Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Imunon (IMNN) has provided an announcement.
Imunon, Inc. has revealed encouraging results from its Phase 2 OVATION 2 trial, which tested IMNN-001 alongside standard chemotherapy treatments for advanced ovarian cancer. The data indicates that the treatment could potentially extend the median time to event and improve overall survival rates, although statistical significance was not reached. Investors and interested parties are invited to a conference call and can access more information via a webcast or the investor presentation on the company’s website.
For an in-depth examination of IMNN stock, go to TipRanks’ Stock Analysis page.